The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019

Amendment of regulation 33 (notification of suspected unexpected serious adverse reactions)

This section has no associated Explanatory Memorandum

14.—(1) Regulation 33 is amended as follows.

(2) Omit paragraph (1)(b)(ii).

(3) Omit paragraph (3)(b).

(4) Omit paragraph (4).

(5) Omit paragraph (6)(b), and the “and” immediately preceding it.